Ruxolitinib: In the treatment of myelofibrosis

Drugs

Volumn 72, Issue 16, 2012, Pages 2117-2127

  Yang, Lily P H ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Myelofibrosis; Ruxolitinib

Indexed keywords

ERYTHROMYCIN; KETOCONAZOLE; PLACEBO; RIFAMPICIN; RUXOLITINIB;

ABDOMINAL PAIN; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; BIOEQUIVALENCE; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEVER; HUMAN; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MYELOFIBROSIS; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHARMACODYNAMICS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SPLEEN SIZE; STEADY STATE; THROMBOCYTOPENIA;

HUMANS; JANUS KINASE 1; JANUS KINASE 2; PRIMARY MYELOFIBROSIS; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84867728023     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11209340-000000000-00000     Document Type: Article

References (35)

1. Klco JM, Vij R, Kreisel FH, et al. Molecular pathology of myeloproliferative neoplasms. Am J Clin Pathol 2010 Apr; 133 (4): 602-15
2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009 Jul 30; 114 (5): 937-51
3. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008 Feb; 22 (2): 437-8
4. Office of Rare Diseases Research, US National Insitutes of Health. Genetic and rare disease information center: myelofibrosis [online]. Available from URL: http://rare diseases.info.nih.gov/GARD/Condition/8618/Myelofibrosis. aspx [Accessed 2012Mar 14]
5. Orphanet. Myelofibrosis with myeloid metaplasia [online]. Available from URL: http://www.orpha.net/consor/cgibin/OC-Exp.php?lng=EN&Expert=824 [Accessed 2012 Mar 14]
6. Gregory SA, Mesa RA, Hoffman R, et al. Clinical and laboratory features of myelofibrosis and limitations of current therapies. Clin Adv Hematol Oncol 2011 Sep; 9 (9 Suppl. 22): 1-16
7. Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 2011 Jan; 25 (1): 82-8
8. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011 Feb 20; 29 (6): 761-70
9. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011 Feb 10; 29 (5): 573-83
10. Tefferi A. How I treat myelofibrosis. Blood 2011 Mar 31; 117 (13): 3494-504
11. Reddy MM, Deshpande A, Sattler M. Targeting JAK2 in the therapy of myeloproliferative neoplasms. Expert Opin Ther Targets Mar; 16 (3): 313-24
12. Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 2008 Aug; 19 (4): 385-93
13. Ferrajoli A, Faderl S, Ravandi F, et al. The JAK-STAT pathway: a therapeutic target in hematologicalmalignancies. Curr Cancer Drug Targets 2006 Dec; 6 (8): 671-9
14. Incyte Corporation. Jakafi(ruxolitinib) oral tablets: US prescribing information [online]. Available from URL: http://www.incyte.com/products/ uspijakafi.pdf [Accessed 2012 Feb 27]
15. European Medicines Agency. Jakavi (ruxolitinib): EU summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/002464/WC 500133223.pdf [Accessed 2012 Oct 8]
16. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2012 Apr 15; 115 (15): 3109-17
17. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in myelofibrosis.NEngl J Med 2010 Sep 16; 363 (12): 1117-27
18. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012 Mar 1; 366 (9): 799-807
19. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012 Mar 1; 366 (9): 787-98
20. Vannucchi AM, Kiladjian JJ, Gisslinger H, et al. Reductions in JAK2V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT) [abstract no. 6514]. J Clin Oncol 2012 May 20; 30 (15 Suppl.)
21. Shi JG, Chen X, McGee RF, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol 2011Dec; 51 (12): 1644-54
22. Deshpande A, Reddy MM, Schade GO, et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 2012 Apr; 26 (4): 708-15
23. Hornakova T, Springuel L, Devreux J, et al. Oncogenic JAK1 and JAK2-activating mutations resistant to ATPcompetitive inhibitors. Haematologica 2011 Jun; 96 (6): 845-53
24. Yang Y, Groshong JS, Matta H, et al. Constitutive NFkappB activation confers interleukin 6 (IL6) independence and resistance to dexamethasome and Janus kinase inhibitor INCB018424 in murine plasmacytoma cells. J Biol Chem 2011 Aug 12; 284 (32): 27988-97
25. Shilling AD, Nedza FM, Emm T, et al. Metabolism, excretion and pharmacokinetics of [14C]-INCB018424, a selective JAK1/2 inhibitor, in humans. Drug Metab Dispos 2010 Nov; 38 (11): 2023-31
26. Chen X, Liu X, Peng S, et al. Population pharmacokinetic analysis of ruxolitinib in subjects with myelofibrosis [abstract no. PI-97]. Clin Pharmacol Ther 2012 Mar; 91 Suppl. 1s: S44
27. Ogama Y, Mineyame T, Yamamoto A, et al. Safety and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers: placebo-controlled, double-blind, doseescalation phase 1 study [abstract no. 5162]. Blood 2011 Nov 18; 118 (21)
28. Shi J, Chen X, McGee R, et al. Effects of various degrees of renal impairment and hemodialysis on the pharmacokinetics and pharmacodynamics of INCB018424 [abstract no. PIII-53]. Clin Pharmacol Ther 2010 Feb; 87 Suppl. 1s: S84
29. Chen X, Shi J, McGee R, et al. The effect of various degrees of hepatic dysfunction on the pharmacokinetics of INCB018424 [abstract no. PIII-59]. Clin Pharmacol Ther 2010 Feb; 87 Suppl. 1: S86
30. Shi JG, Chen X, Emm T, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol 2012 Jun; 52 (6): 809-18
31. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis [letter]. N Engl J Med 2011 Oct 13; 365 (15): 1455-7
32. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011; 86 (12): 1188-91
33. Gisslinger H, McMullin MF, Jaekel N, et al. A phase Ib, open-label, dose-finding study of ruxolitinib in patients (pts) with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF) and baseline platelets (PLTs) 50 to <100 · 109/l [abstract no. TPS6642]. J Clin Oncol 2012 May 20; 30 (15 Suppl.)
34. Talpaz M, Hamburg SI, Jamieson K, et al. Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50-100 · 109/L [abstract no. 6630]. J Clin Oncol 2012 May 20; 30 (15 Suppl.)
35. le Coutre PD, Gisslinger H, Zachee P, et al. An open-label, multicentre, expanded access study assessing the safety and efficacy of oral ruxolitinib administered to patients with primary myelofibrosis (PMF), post-polycythemia myelofibrosis (PPV-MF) or post-essential throbocythemia melofibrosis (PET-MF) [abstract no. TPS6640]. J Clin Oncol 2012 May 20; 30 (15 Suppl.)